These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27749923)

  • 1. Differential Adverse Event Profiles Associated with BCG as a Preventive Tuberculosis Vaccine or Therapeutic Bladder Cancer Vaccine Identified by Comparative Ontology-Based VAERS and Literature Meta-Analysis.
    Xie J; Codd C; Mo K; He Y
    PLoS One; 2016; 11(10):e0164792. PubMed ID: 27749923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports.
    Guo W; Deguise J; Tian Y; Huang PC; Goru R; Yang Q; Peng S; Zhang L; Zhao L; Xie J; He Y
    Front Pharmacol; 2022; 13():870599. PubMed ID: 35814246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.
    Sarntivijai S; Xiang Z; Shedden KA; Markel H; Omenn GS; Athey BD; He Y
    PLoS One; 2012; 7(11):e49941. PubMed ID: 23209624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant BCGs for tuberculosis and bladder cancer.
    Singh AK; Srikrishna G; Bivalacqua TJ; Bishai WR
    Vaccine; 2021 Dec; 39(50):7321-7331. PubMed ID: 34593271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Bacillus Calmette-Guerin in superficial bladder cancer: a review.
    Talug C; Brown ET; Zaslau S; Kandzari SJ
    W V Med J; 2009; 105(3):17-9. PubMed ID: 19456033
    [No Abstract]   [Full Text] [Related]  

  • 7. OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines.
    Zi W; Yang Q; Su J; He Y; Xie J
    Heliyon; 2022 Nov; 8(11):e11515. PubMed ID: 36411908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacille Calmette-Guérin vaccine.
    Wittes RC
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S115-21. PubMed ID: 11010836
    [No Abstract]   [Full Text] [Related]  

  • 9. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
    Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
    South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacillus Calmette-Guérin (BCG) vaccine safety surveillance in the Korea Adverse Event Reporting System using the tree-based scan statistic and conventional disproportionality-based algorithms.
    Kim JH; Lee H; Shin JY
    Vaccine; 2020 May; 38(21):3702-3710. PubMed ID: 32278521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
    Alexandroff AB; Nicholson S; Patel PM; Jackson AM
    Immunotherapy; 2010 Jul; 2(4):551-60. PubMed ID: 20636008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates.
    Méndez-Samperio P
    Scand J Immunol; 2019 Oct; 90(4):e12772. PubMed ID: 31055842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapeutically induced cutaneous tuberculosis after BCG injection in a patient with pelvic osteosarcoma.
    Zoccali G; Cota C; Marolda G; Ferraresi V; Giuliani M; Zoccali C
    Surg Infect (Larchmt); 2012 Dec; 13(6):406-8. PubMed ID: 23240721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
    Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
    Front Immunol; 2018; 9():2371. PubMed ID: 30386336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current perspective in tuberculosis vaccine development for high TB endemic regions.
    Husain AA; Daginawala HF; Singh L; Kashyap RS
    Tuberculosis (Edinb); 2016 May; 98():149-58. PubMed ID: 27156631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP; Greenberg RE; Steinberg GD
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare-Associated Mycobacterium bovis-Bacille Calmette-Guérin (BCG) Infection in Cancer Patients Without Prior BCG Instillation.
    Meije Y; Martínez-Montauti J; Caylà JA; Loureiro J; Ortega L; Clemente M; Sanz X; Ricart M; Santomà MJ; Coll P; Sierra M; Calsina M; Vaqué M; Ruiz-Camps I; López-Sánchez C; Montes M; Ayestarán A; Carratalà J; Orcau À
    Clin Infect Dis; 2017 Oct; 65(7):1136-1143. PubMed ID: 28575173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacillus Calmette-Guérin Cases Reported to the National Tuberculosis Surveillance System, United States, 2004-2015.
    Wansaula Z; Wortham JM; Mindra G; Haddad MB; Salinas JL; Ashkin D; Morris SB; Grant GB; Ghosh S; Langer AJ
    Emerg Infect Dis; 2019 Mar; 25(3):451-456. PubMed ID: 30789145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.